Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment.
about
Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 March 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prospective longitudinal study ...... omide or bortezomib treatment.
@en
Prospective longitudinal study ...... omide or bortezomib treatment.
@nl
type
label
Prospective longitudinal study ...... omide or bortezomib treatment.
@en
Prospective longitudinal study ...... omide or bortezomib treatment.
@nl
prefLabel
Prospective longitudinal study ...... omide or bortezomib treatment.
@en
Prospective longitudinal study ...... omide or bortezomib treatment.
@nl
P2093
P2860
P356
P1433
P1476
Prospective longitudinal study ...... omide or bortezomib treatment.
@en
P2093
C Kyriakou
I Vande Broek
M T Petrucci
P2860
P2888
P356
10.1038/BCJ.2017.20
P577
2017-03-17T00:00:00Z